Traumatic Brain Injury Market: Epidemiology, Therapies, Companies, DelveInsight | veriNOS pharmaceuticals GmbH, Cellvation, Abalonex, Hope Biosciences

Traumatic Brain Injury emerging therapies, such as OXE103 (Ghrelin), HB-AdMSCs, ONP-002 /PRV-002, CEVA101, MR-301, NE3107a, and others, are expected to boost the Traumatic Brain Injury Market in the upcoming years.

DelveInsight has launched a new report on "Traumatic Brain Injury - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Traumatic Brain Injury, historical and forecasted epidemiology as well as the Traumatic Brain Injury market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Traumatic Brain Injury market report @ https://www.delveinsight.com/report-store/traumatic-brain-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Traumatic Brain Injury Market Report:

The traumatic brain injury (TBI) market is expected to show steady growth over the forecast period (2025-2034), largely driven by the introduction of novel therapies. According to DelveInsight, there were approximately 4.3 million incident TBI cases across the 7MM in 2024, with projections indicating a continued rise in cases during the forecast period. The United States reported the highest number of cases, followed by Japan, Germany, France, and the UK.
In terms of market value, the U.S. led in 2024, with standard care generating around USD 1.12 billion. Treatment options largely consist of off-label use of various medications-such as antidepressants, antiepileptics, antipsychotics, analgesics, antacids, and other symptom-relief drugs. Notably, 45-85% of TBI patients are prescribed psychotropic and pain medications, highlighting the high reliance on pharmacologic management.
AKUUGO, a promising therapy for chronic TBI, has received multiple regulatory designations recognizing its potential.
Emerging therapies such as ONP-002, CEVA101, and others are expected to reshape the TBI treatment landscape, contributing to overall market expansion. Companies like Oragenics, Beyond Barriers Therapeutics, and Noveome are exploring intranasal routes of administration, while Neuroplast is investigating intrathecal delivery.
There is also a growing recognition of the need to manage both psychiatric and non-neurological symptoms in TBI patients-particularly in females-and to carefully evaluate medication regimens to reduce risks associated with polypharmacy. As research advances and new therapies gain approval, the TBI market is set for significant growth throughout the next decade.
In 2024, the United States recorded the highest number of traumatic brain injury (TBI) incident cases among the 7MM, with an estimated 3,042,000 cases. Within the EU4 and the UK, Germany reported the highest number of cases, followed by France, while Spain had the lowest. In the United Kingdom specifically, around 125,000 adults and 49,000 children were affected by TBI during the same year.
On April 2, 2024, the FDA approved Abbott's i-STAT TBI cartridge (whole blood tool on the portable Alinity platform), offering lab-quality results in just 15 minutes to aid in concussion assessment and reduce unnecessary CT scans
Key Traumatic Brain Injury companies such as veriNOS pharmaceuticals GmbH, Cellvation, Abalonex, Hope Biosciences, and others are evaluating new drugs for Traumatic Brain Injury to improve the treatment landscape.
Promising Traumatic Brain Injury therapies include OXE103 (Ghrelin), HB-AdMSCs, ONP-002 /PRV-002, CEVA101, MR-301, NE3107a, and others.

Traumatic Brain Injury Overview

Traumatic brain injury (TBI) refers to sudden brain damage resulting from a forceful blow or jolt to the head. It commonly occurs due to motor vehicle accidents, falls, sports-related impacts, or physical assaults. TBIs can vary in severity, ranging from mild concussions to serious injuries that cause lasting brain impairment. The damage that happens at the moment of impact is called the primary injury, which may affect a specific brain region or the entire brain. Although a skull fracture may occur, it is not always present. During trauma, the brain may collide with the inside of the skull, leading to bruising, bleeding, and nerve fiber damage.

TBI symptoms depend on the severity of the injury and may be classified as mild, moderate, or severe. In mild cases, individuals might remain conscious or briefly lose consciousness. Symptoms may include headache, dizziness, confusion, blurred vision, fatigue, ringing in the ears, sleep disturbances, mood or behavioral changes, and difficulties with memory or concentration.

In moderate to severe cases, these symptoms can be more intense and may also involve persistent or worsening headaches, repeated vomiting or nausea, seizures, inability to wake up, enlarged pupils, slurred speech, weakness or numbness in limbs, poor coordination, and heightened confusion or agitation.

Traumatic Brain Injury Market Outlook

Treatment for traumatic brain injury (TBI) generally includes medical care, rehabilitation, and supportive therapies aimed at managing symptoms and enhancing recovery. The approach varies significantly depending on the severity of the injury-ranging from routine cognitive therapy sessions to more intensive procedures like bilateral decompressive craniotomies. Although clinical guidelines exist for TBI management, they must be adapted to the specific needs and context of each patient.

Current treatment options primarily focus on symptom management and may include antidepressants, antiepileptics, antipsychotics, analgesics, antacids, and other supportive medications. These drugs help address the neuropsychiatric, neurocognitive, and neurobehavioral consequences commonly associated with brain injury.

Discover how the Traumatic Brain Injury market is rising in the coming years @ https://www.delveinsight.com/sample-request/traumatic-brain-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Traumatic Brain Injury Marketed Drugs

AKUUGO (Vandefitemcel): SanBio

Traumatic Brain Injury Emerging Drugs
OXE103: Oxeia Biopharmaceuticals
ONP-002: Oragenics

Scope of the Traumatic Brain Injury Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Traumatic Brain Injury Companies: veriNOS pharmaceuticals GmbH, Cellvation, Abalonex, Hope Biosciences, and others
Key Traumatic Brain Injury Therapies: OXE103 (Ghrelin), HB-AdMSCs, ONP-002 /PRV-002, CEVA101, MR-301, NE3107a, and others
Traumatic Brain Injury Therapeutic Assessment: Traumatic Brain Injury current marketed and Traumatic Brain Injury emerging therapies
Traumatic Brain Injury Market Dynamics: Traumatic Brain Injury market drivers and Traumatic Brain Injury market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Traumatic Brain Injury Unmet Needs, KOL's views, Analyst's views, Traumatic Brain Injury Market Access and Reimbursement

To know what's more in our Traumatic Brain Injury report, visit https://www.delveinsight.com/report-store/traumatic-brain-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Traumatic Brain Injury Market Report:
Traumatic Brain Injury market report covers a descriptive overview and comprehensive insight of the Traumatic Brain Injury Epidemiology and Traumatic Brain Injury market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Traumatic Brain Injury market report provides insights into the current and emerging therapies.
The Traumatic Brain Injury market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Traumatic Brain Injury market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Traumatic Brain Injury market.

Got queries? Click here to know more about the Traumatic Brain Injury market Landscape https://www.delveinsight.com/sample-request/traumatic-brain-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Traumatic Brain Injury Patient Share (%) Overview at a Glance
5. Traumatic Brain Injury Market Overview at a Glance
6. Traumatic Brain Injury Disease Background and Overview
7. Traumatic Brain Injury Epidemiology and Patient Population
8. Country-Specific Patient Population of Traumatic Brain Injury
9. Traumatic Brain Injury Current Treatment and Medical Practices
10. Unmet Needs
11. Traumatic Brain Injury Emerging Therapies
12. Traumatic Brain Injury Market Outlook
13. Country-Wise Traumatic Brain Injury Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Traumatic Brain Injury Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Traumatic Brain Injury Market Outlook 2034 https://www.delveinsight.com/report-store/traumatic-brain-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Traumatic Brain Injury Pipeline Insights, DelveInsight

"Traumatic Brain Injury Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Traumatic Brain Injury market. A detailed picture of the Traumatic Brain Injury pipeline landscape is provided, which includes the disease overview and Traumatic Brain Injury treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.